Conditionally activatable antibodies are an emerging class of engineered biologics designed to improve the therapeutic index. The therapeutic index can be defined as the balance between efficacy and toxicity, by restricting antibody activity to disease sites. Within this broader category, ATP-dependent switch antibodies are a mechanistically distinct approach that exploits biochemical features of the tumor microenvironment (TME). The TME refers to the local cellular and molecular environment surrounding a tumor, including immune cells, stromal cells, and soluble factors. A defining characteristic of many TMEs is an elevated concentration of extracellular adenosine triphosphate (ATP), a nucleotide that normally functions as an intracellular energy carrier but can accumulate outside cells under conditions such as cellular stress or necrosis. ATP-switch antibodies are engineered so that their antigen binding, which is the interaction between an antibody and its specific molecular target, is dependent on the presence of extracellular ATP, thereby enabling tumor-selective activity.
The defining feature of ATP-switch antibodies is the requirement for ATP as a molecular cofactor. A cofactor is a non-protein molecule that is necessary for the biological activity of a protein. In this context, ATP participates directly in the antibody-antigen interaction. Structural analysis has demonstrated that ATP can bind at the interface between the antibody and the antigen, effectively acting as a molecular bridge that stabilizes the complex.
In the absence of ATP, the antibody exhibits minimal or no binding to its antigen. Meanwhile, in the presence of ATP (at concentrations observed in the TME) the antibody undergoes a functional transition that enables binding. This mechanism differs from traditional antibodies, which bind their targets constitutively (i.e., independently of environmental conditions).
Quantitative studies further support this model by showing that ATP concentrations in tumor interstitial fluid can reach the hundreds of micromolar (μM) range, whereas concentrations in normal tissues are substantially lower. This concentration gradient provides the biochemical basis for spatial selectivity, meaning that antibody activity is preferentially localized to tumor tissue.
One of the most advanced applications of ATP-switch technology is in antibodies targeting CD137, also known as 4-1BB. CD137 is a costimulatory receptor expressed on T cells, where its activation enhances T-cell proliferation and cytotoxic activity. Conventional agonistic antibodies that were designed to activate the receptor rather than block it, have shown anti-tumor potential but have been limited by systemic toxicity, including liver inflammation.
ATP-switch antibodies such as STA551 have been engineered so that CD137 activation occurs only in the presence of extracellular ATP. Preclinical studies demonstrate that these antibodies can induce anti-tumor immune responses across multiple tumor models while avoiding systemic immune activation.
Pharmacokinetic and tissue distribution studies, combined with physiologically based pharmacokinetic (PBPK) modeling, which is a computational approach used to predict drug distribution in the body, have shown that ATP-dependent binding results in preferential accumulation and activity in tumor tissue.
Early clinical evaluation further supports these findings. In a first-in-human study, ATP-switch CD137 antibodies exhibited a manageable safety profile, with evidence of target engagement and immune activation within tumors, including increased expression of CD137 signaling-related genes and infiltration of CD8-positive (CD8⁺) T cells, a subset of cytotoxic T lymphocytes.
Besides CD137, CTLA-4 as a target is another example of the ATP-switch concept. CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is an immune checkpoint receptor that negatively regulates T-cell activation. Antibodies targeting CTLA-4 are designed to increase immune responses against tumors but are often associated with systemic immune-related adverse events.
The novel ATP-dependent antibody ROSE12 has been engineered to bind CTLA-4 only in the presence of extracellular ATP. This design enables selective depletion of regulatory T cells (Tregs), a subset of T cells that suppress immune responses, within tumors through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC). ADCC is an immune process in which effector cells recognize and kill antibody-coated target cells.
Ongoing phase I clinical evaluation (NCT05907980) and the favorable safety profile in non-human primates support the clinical development of ATP-dependent switch antibody platforms for broader cancer immunotherapy applications.
The development of ATP-switch antibodies include key parameters such as:
The affinity of the antibody for ATP, which must align with concentrations found in the TME
The stability of the ternary complex (antibody-ATP-antigen)
The balance between sufficient binding in tumors and minimal binding in normal tissues
In addition, pharmacokinetic behavior is influenced by the conditional nature of binding. Unlike conventional antibodies, which may bind targets systemically, ATP-switch antibodies exhibit context-dependent target engagement, complicating traditional modeling approaches and necessitating specialized frameworks such as PBPK modeling.
ATP-switch antibodies represent one approach within the broader category of conditionally activatable antibodies. Other strategies include:
Protease-activated antibodies, which are unmasked by tumor-associated proteases
pH-dependent antibodies, which bind preferentially in acidic environments
Redox-sensitive systems, which respond to differences in oxidative conditions
Compared to these approaches, ATP-switch antibodies are characterized by:
A non-enzymatic trigger (ATP does not require catalytic processing)
Reversible binding, dependent on ATP concentration
Independence from irreversible structural modifications such as proteolytic cleavage
However, their performance may depend on the degree of ATP elevation in different tumors, introducing potential variability in efficacy.
Ongoing research is exploring the integration of ATP-switch mechanisms with other conditional systems to create multi-input activation strategies, where antibody activity depends on more than one environmental cue. Additional areas of interest include:
Identification of biomarkers to stratify patients based on TME ATP levels
Evaluation of ATP-switch antibodies in combination with other immunotherapies
Investigation of how tumor metabolism influences extracellular ATP availability
A key challenge is the heterogeneity of the TME, as variations in ATP concentration across tumor types or even within a single tumor may affect therapeutic performance.
ATP-dependent switch antibodies represent a mechanistically novel approach to antibody engineering in which antigen binding is contingent upon a small-molecule cofactor enriched in the tumor microenvironment. By exploiting elevated extracellular ATP levels, these antibodies achieve tumor-selective activity without relying solely on differential antigen expression.
Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events a……
Antibody research is increasingly supported by computational methods, such as st……
Multiple myeloma (MM) treatment is increasingly shaped by antibody-based approac……
You can also contact us on the Scientist and Science Exchange marketplaces.
